Separate names with a comma.
ETON =MC $96 M--3x FDA DECISIONS in this year ,LOW FLOAT =CHEAPEST and MOST attractive FDA Gem in 2020 a potential 10 bagger here [IMG]
Here is an extremely underpriced (trading under cash) and undiscovered biotech stock : (TRVI-DD) Market Cap $49 million / Cash $53 Million or...
Still a massive buying opportunity after FDA approval at current laughable valuation of only $87 million Baudax Bio's (BXRX) Non-opioid Pain...
17 days till FDA decision ,, still a great buying opp
GREAT buying opportunity here ....Price 0.35 -Market Cap $33 M--FDA DECISION for Migraine drug & Launch of Cannabis Products both expected during...
FDA approval is very likely this time ,, Approval would make this undiscovered stock worth more than $50 per share...
Any dip here is a great buying opp ahead of the FDA decision next month ,stock likely tohit $10 in the coming days .GL
Great News out today ....FDA DECISION NEXT MONTH (FDA) has set a PDUFA goal date of February 20, 2020...
Baudax Bio Inc. (BXRX) PT Raised to $12 at Oppenheimer...
Put a high gtc sell order in like $50 for your shrs to reduce the available shrs on market this supports the sp even more .thank you Q:What can...
stock exploding again with such extreme low float and MASSIVE potential this stock could explode towards $100 in no time .GL
RSLS =MC $2.5 M Cash $7.7M / O/S 353 K most of these shares owned by Armistice who still continue buying more current Float is only 100 Kshares ....
Market Cap $10 M -- Cash $7 M-- Shares Out 4.7 M --NASH Phase 2 results imminent ($35+ BILLION MKT with no approved treatment to date --...
GREAT buying opp ahead of the NDA resubmission likely to hit the wire next week ...Could minimum double before FDA decision which will ouccur 2...
Market Cap $11 M --Cash $18 M --Shares Out only 8.5M --2 BIG Phase 3 Readouts targeting posttraumatic stress disorder (PTSD) & Fibromyalgia which...
EXPLODINGGG again ..still a pure gift under $1 [IMG]
Market Cap $16 M --Cash $18.5 M or Cash untill 2023+ --NO DEBT --BIG Orphan Drug close to Approval (2H 2020) -three Phase 3 Programs in different...
more good news out today from CYTR´s partner Orphazyme Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in...
Running higher stock ´could hit one $1+ very soon ..stock is just a pure gift at current $12 million valuation...
